Aptamer Group collaborates with world-leading pharmaceutical company to evaluate Optimer technology
York, UK (May 28, 2021) – Aptamer Group, the developer of diagnostic and therapeutic Optimer™ reagents, today announced that it has signed an agreement with the multinational pharmaceutical and biopharmaceutical company Takeda Pharmaceutical Company Limited (“Takeda”).
The agreement will allow Aptamer Group to assess its Optimer technology with a new target class, with the potential for incorporation into Takeda’s drug development process. Following the development of specific Optimer reagents to the agreed range of targets, the Optimers will be available to Takeda to evaluate for the feasibility of working with their drug compounds.
Share this article
Share this article
BIRMINGHAM, Ala., May 25, 2021 /PRNewswire/ Leading patient engagement platform Pack Health today announces the launch of a new mental health engagement program for frontline healthcare providers in the U.S. The program is designed to provide remote mental well-being support to healthcare providers who are experiencing increased stress, anxiety, depression and burnout due to the COVID-19 pandemic.
Pack Health Offers Support for Clinicians Experiencing Burnout & Mental Health Challenges Due to COVID-19
The program, available at no charge to participants, will include one-to-one health coaching with a personal Health Advisor and resources that help providers manage stress and identify barriers to their own self-care. Pack Health aims to enroll physicians, nurses, and other frontline healthcare providers into the program over the next several months.
May 24, 2021 healthcare
Takeda Presents Updated Results for Mobocertinib, Further Substantiating the Clinical Benefit in Patients with EGFR Exon20 Insertion+ mNSCLC
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced updated data from the Phase 1/2 trial of mobocertinib (TAK-788) orally administered in patients with epidermal growth factor receptor (EGFR) Exon20 insertion mutation-positive (insertion+) metastatic non-small cell lung cancer (mNSCLC) who received prior platinum-based chemotherapy. The results showed mobocertinib continued to demonstrate clinically meaningful benefit after over a year of follow up and will be presented at the virtual 57th American Society of Clinical Oncology (ASCO) Annual Meeting on June 4.
“Patients with EGFR Exon20 insertion+ mNSCLC have no proven targeted therapy options,” said Suresh S. Ramalingam, MD, Deputy Director of Winship Cancer Institute of Emory University. “The updated r